Skip to content
Head to head

Arcus Biosciences vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: RCUS · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

RCUS -21.9%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
RCUSVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price15.62515.02
Change today-1.01%-1.08%
1-year return-26.4%+22.0%
Market cap$2.25B$130.58B
52-week range15.56 – 31.74412.27 – 568.67
Valuation
P/E (TTM)-4.2933.14
P/E percentile, own 5-yr range46th99th
P/B6.286.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-3.2915.32
Net profit (TTM)$-473.73M$3.88B
Revenue (TTM)$100.00M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)-65.4%+11.8%
Gross margin--85.5%
Operating margin-475.0%33.1%
Net margin-453.0%30.7%
Free cash flow (TTM)$-466.00M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership87.8%96.8%
Insider activity (12mo)22 buy / 28 sell28 buy / 22 sell
Short interest (% of float)9.3%1.9%
Analyst consensus83% buy / 17% hold (12)95% buy / 5% hold (21)
Analyst price target$42 (+167%)$624 (+21%)
StockVane view
StockVane Quant RatingD (18)C (68)
Company
Employees6016,400
Founded20151989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.